Cysteamine Therapy for Major Depressive Disorder

Terminated 3 enrolled Icahn School of Medicine at Mount Sinai

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether cysteamine bitartrate, an FDA-approved drug for a non-psychiatric condition, is safe and effective for the treatment of major depression.

Timeline

Start: 2008-07
Primary completion: 2009-05
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cysteamine	Unknown	300 mg	Oral

Cysteamine Therapy for Major Depressive Disorder

Summary

Timeline

Drugs

Indications